Phase III Results for Rucaparib in Ovarian Cancer

December 14, 2017
Jonathan Ledermann, MD

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses phase III results of a study of rucaparib versus placebo following response to platinum-based chemotherapy for recurrent ovarian cancer.